4//SEC Filing
Seely Lynn 4
Accession 0001415889-25-021694
CIK 0001806952other
Filed
Aug 12, 8:00 PM ET
Accepted
Aug 13, 9:10 PM ET
Size
7.8 KB
Accession
0001415889-25-021694
Insider Transaction Report
Form 4
Seely Lynn
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2025-08-11$10.53/sh−391$4,116→ 35,234 total - Sale
Common Stock
2025-08-12$10.34/sh−406$4,197→ 34,828 total
Footnotes (6)
- [F1]Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
- [F2]The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.045 to $11.00 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- [F3]On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split.
- [F4]Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
- [F5]The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.120 to $10.415 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- [F6]On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split.
Documents
Issuer
Lyell Immunopharma, Inc.
CIK 0001806952
Entity typeother
Related Parties
1- filerCIK 0001327111
Filing Metadata
- Form type
- 4
- Filed
- Aug 12, 8:00 PM ET
- Accepted
- Aug 13, 9:10 PM ET
- Size
- 7.8 KB